Dividends Calendar Earnings Calendar
ALXN

ALXN | Alexion Pharmaceuticals Inc

168.34 -1.93 (-1.13%) 
Healthcare sector
Alexion Pharmaceuticals Inc

Company profile

  • Industry: Biotechnology
  • Sector: Healthcare
  • Headquarters:   New Haven, Connecticut, United States
  • Number of employees::   2,525 (2017)
Investor Relations : ir.alexion.com

Company profile

Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies.

About the Company

Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. The company is also involved in immune system research related to autoimmune diseases.

  • Subsidiaries:   Alexion International Sarl, Syntimmune, Inc.
  • Revenue: 3.551 billion USD (2017)

Address

121 Seaport Blvd
Boston, MA 02210

Products & Services

  • Soliris

    Key Persons / Board of Directors

    • CEO :  Ludwig N. Hantson (Mar 2017–)


    Jump to (Finance sites)

    Google     
             

    Research 


    Investor page

    ir.alexion.com

    If you are looking for News & events, Press Release, they are available on their Investors Relationssite.


    Consensus
    BUY 24
    HOLD 76
    SELL 0

    Their Official Profiles 

    WikipediaLinkedInYoutube

    Peers / Similar stocks 

    xlv 

    Other stocks 

    mmm rht fb gnc dltr kr se aobc vsto tal levi info 

    Support this project

    If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
    More features coming soon :)

    Social Media 




    Recommended Books

    The Intelligent Investor
    Buy on Amazon

    Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.

    The best book on investing ever written.
    -- Warren Buffet